Gheewala Pankti A, Peterson Gregory M, Zaidi Syed Tabish R, Jose Matthew D, Castelino Ronald L
Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Private Bag 26, Hobart, 7001, Australia.
School of Medicine, Faculty of Health, University of Tasmania, Private Bag 34, Hobart, TAS, 7000, Australia.
Int J Clin Pharm. 2018 Apr;40(2):458-463. doi: 10.1007/s11096-018-0603-2. Epub 2018 Feb 13.
Patient satisfaction is an important determinant of the feasibility and sustainability of community pharmacy screening services. However, few studies have evaluated this, with no such study performed for a chronic kidney disease risk assessment service.
The aim was to determine patient satisfaction with a chronic kidney disease risk assessment service performed in community pharmacies.
Community pharmacies in the state of Tasmania, Australia.
An anonymous nine-item satisfaction survey, with Likert-type scales, was developed following a literature review of existing surveys. Reliability of the nine-item scale was determined using Cronbach's alpha. Patients were asked an additional question on willingness to pay, with choices of amount from $5 to $25. The satisfaction survey was mailed to 389 patients who participated in the chronic kidney disease risk assessment study.
Patient level of satisfaction with and willingness to pay for the chronic kidney disease service.
Responses from 143 participants were included in the final analysis. Cronbach's alpha for the nine-item satisfaction scale was 0.87. The majority of participants agreed that the time required to undergo the risk assessment process was justified (90.2%); overall, they were satisfied with the chronic kidney disease risk assessment service (90.0%) and they felt comfortable with the pharmacist referring their results to their doctor (88.9%). Of 136 participants who answered the question on willingness to pay, 62.9% indicated that they would pay for the chronic kidney disease service. Of these, 29.2, 25.8 and 19.1% were willing to pay $20, $10 and $5, respectively.
Patient satisfaction with the community pharmacy-based chronic kidney disease risk assessment was high. These findings provide support for the implementation of the service within community pharmacy practice.
患者满意度是社区药房筛查服务可行性和可持续性的重要决定因素。然而,很少有研究对此进行评估,尚无针对慢性肾脏病风险评估服务的此类研究。
旨在确定患者对社区药房开展的慢性肾脏病风险评估服务的满意度。
澳大利亚塔斯马尼亚州的社区药房。
在对现有调查进行文献综述后,制定了一项包含九个项目的匿名满意度调查,采用李克特量表。使用克朗巴哈系数法确定该九个项目量表的信度。还向患者询问了一个关于支付意愿的附加问题,支付金额选项为5美元至25美元。将满意度调查问卷邮寄给389名参与慢性肾脏病风险评估研究的患者。
患者对慢性肾脏病服务的满意度水平及支付意愿。
最终分析纳入了143名参与者的回复。九个项目满意度量表的克朗巴哈系数为0.87。大多数参与者认为进行风险评估过程所需的时间是合理的(90.2%);总体而言,他们对慢性肾脏病风险评估服务感到满意(90.0%),并且对药剂师将评估结果转交给医生这一做法感到放心(88.9%)。在136名回答了支付意愿问题的参与者中,62.9%表示愿意为慢性肾脏病服务付费。其中,分别有29.2%、25.8%和19.1%的人愿意支付20美元、10美元和5美元。
患者对基于社区药房的慢性肾脏病风险评估满意度较高。这些研究结果为在社区药房实践中开展该服务提供了支持。